hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT01365936
• Date of registration: 31/05/2011
• Primary sponsor: Zekai Tahir Burak Maternity and Teaching Hospital
• Public title: hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF
• Scientific title: Influence of Ovarian Stimulation With hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF
• Date of first enrolment: January 2008
• Target sample size: 80
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT01365936
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Countries of recruitment

Turkey

Contacts

• Name: Figen A Turkcapar, MD
• Affiliation: Zekai Tahir Burak Women's Health Research and Training Hospital

Key inclusion & exclusion criteria

Inclusion Criteria:

- Women with PCOS

Exclusion Criteria:

- Patients older than 38 years or with serum FSH level =12mIU/ml and a history of
ovarian surgery were excluded from the study



Age minimum: 20 Years
Age maximum: 38 Years
Gender: Female

Health Condition(s) or Problem(s) studied

Polycystic Ovary Syndrome

Intervention(s)

Drug: HMG

Drug: rFSH

Primary Outcome(s)

peak serum E2 levels [Time Frame: 6 months]

the incidence of OHSS [Time Frame: 6 Months]

Secondary Outcome(s)

fertilization rate [Time Frame: 6 months]

number of intermediate follicles [Time Frame: 6 months]

the need of coasting, [Time Frame: 6 months]

Secondary ID(s)

ZTBIVF1

Source(s) of Monetary Support

Please refer to primary and secondary sponsors